Cargando…
Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series
(1) Background: Complement system activation has been proposed as one of the different factors that contribute to Multiple Sclerosis (MS) pathogenesis. In this study, we aimed to describe the potential effects of eculizumab, an anticomplement therapy, on MS disease activity in a cohort of relapsing–...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533854/ https://www.ncbi.nlm.nih.gov/pubmed/34679405 http://dx.doi.org/10.3390/brainsci11101341 |
_version_ | 1784587413905997824 |
---|---|
author | Allinovi, Marco Bellinvia, Angelo Pesce, Francesco Milan Manani, Sabrina Razzolini, Lorenzo Brezzi, Brigida Protopapa, Paolo Mantero, Vittorio Caroti, Leonardo Cirami, Calogero Lino Amato, Maria Pia Del Vecchio, Lucia |
author_facet | Allinovi, Marco Bellinvia, Angelo Pesce, Francesco Milan Manani, Sabrina Razzolini, Lorenzo Brezzi, Brigida Protopapa, Paolo Mantero, Vittorio Caroti, Leonardo Cirami, Calogero Lino Amato, Maria Pia Del Vecchio, Lucia |
author_sort | Allinovi, Marco |
collection | PubMed |
description | (1) Background: Complement system activation has been proposed as one of the different factors that contribute to Multiple Sclerosis (MS) pathogenesis. In this study, we aimed to describe the potential effects of eculizumab, an anticomplement therapy, on MS disease activity in a cohort of relapsing–remitting (RR) MS patients who discontinued IFN-β therapy due to IFN-β-related thrombotic microangiopathy (TMA) onset. (2) Methods: In this retrospective observational multicentric study, we searched for all patients with MS treated by eculizumab with a survey of several nephrological and neurological centers (over 45 centers). (3) Results: Nine patients were included. The mean follow-up time under eculizumab was 3.72 ± 2.58 years. There were no significant differences in disease activity (EDSS, relapses, new T2, and/or Gd-enhancing lesions at MRI) considering the two years before and after eculizumab therapy. No adverse events potentially related to eculizumab therapy were reported during follow-up. (4) Conclusions: In this preliminary study, we described a good safety profile for eculizumab therapy in MS. However, the available data are not sufficient to make firm conclusions about the possible efficacy of eculizumab as a disease-modifying therapy for MS patients. |
format | Online Article Text |
id | pubmed-8533854 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85338542021-10-23 Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series Allinovi, Marco Bellinvia, Angelo Pesce, Francesco Milan Manani, Sabrina Razzolini, Lorenzo Brezzi, Brigida Protopapa, Paolo Mantero, Vittorio Caroti, Leonardo Cirami, Calogero Lino Amato, Maria Pia Del Vecchio, Lucia Brain Sci Article (1) Background: Complement system activation has been proposed as one of the different factors that contribute to Multiple Sclerosis (MS) pathogenesis. In this study, we aimed to describe the potential effects of eculizumab, an anticomplement therapy, on MS disease activity in a cohort of relapsing–remitting (RR) MS patients who discontinued IFN-β therapy due to IFN-β-related thrombotic microangiopathy (TMA) onset. (2) Methods: In this retrospective observational multicentric study, we searched for all patients with MS treated by eculizumab with a survey of several nephrological and neurological centers (over 45 centers). (3) Results: Nine patients were included. The mean follow-up time under eculizumab was 3.72 ± 2.58 years. There were no significant differences in disease activity (EDSS, relapses, new T2, and/or Gd-enhancing lesions at MRI) considering the two years before and after eculizumab therapy. No adverse events potentially related to eculizumab therapy were reported during follow-up. (4) Conclusions: In this preliminary study, we described a good safety profile for eculizumab therapy in MS. However, the available data are not sufficient to make firm conclusions about the possible efficacy of eculizumab as a disease-modifying therapy for MS patients. MDPI 2021-10-11 /pmc/articles/PMC8533854/ /pubmed/34679405 http://dx.doi.org/10.3390/brainsci11101341 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Allinovi, Marco Bellinvia, Angelo Pesce, Francesco Milan Manani, Sabrina Razzolini, Lorenzo Brezzi, Brigida Protopapa, Paolo Mantero, Vittorio Caroti, Leonardo Cirami, Calogero Lino Amato, Maria Pia Del Vecchio, Lucia Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series |
title | Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series |
title_full | Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series |
title_fullStr | Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series |
title_full_unstemmed | Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series |
title_short | Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series |
title_sort | safety and efficacy of eculizumab therapy in multiple sclerosis: a case series |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533854/ https://www.ncbi.nlm.nih.gov/pubmed/34679405 http://dx.doi.org/10.3390/brainsci11101341 |
work_keys_str_mv | AT allinovimarco safetyandefficacyofeculizumabtherapyinmultiplesclerosisacaseseries AT bellinviaangelo safetyandefficacyofeculizumabtherapyinmultiplesclerosisacaseseries AT pescefrancesco safetyandefficacyofeculizumabtherapyinmultiplesclerosisacaseseries AT milanmananisabrina safetyandefficacyofeculizumabtherapyinmultiplesclerosisacaseseries AT razzolinilorenzo safetyandefficacyofeculizumabtherapyinmultiplesclerosisacaseseries AT brezzibrigida safetyandefficacyofeculizumabtherapyinmultiplesclerosisacaseseries AT protopapapaolo safetyandefficacyofeculizumabtherapyinmultiplesclerosisacaseseries AT manterovittorio safetyandefficacyofeculizumabtherapyinmultiplesclerosisacaseseries AT carotileonardo safetyandefficacyofeculizumabtherapyinmultiplesclerosisacaseseries AT ciramicalogerolino safetyandefficacyofeculizumabtherapyinmultiplesclerosisacaseseries AT amatomariapia safetyandefficacyofeculizumabtherapyinmultiplesclerosisacaseseries AT delvecchiolucia safetyandefficacyofeculizumabtherapyinmultiplesclerosisacaseseries |